Rheovector is a development-stage company focused on delivering new diagnostics for earlier and more accurate prediction of acute cardiovascular events.

Our purpose is simple: to reduce cardiovascular mortality and the overall cost of healthcare.

Through basic science and clinical research, we are validating a pipeline of proprietary technologies that incorporate the most advanced in vitro diagnostics and vascular imaging tools. We are working to deliver new fluid dynamic markers that more accurately predict the progression of atherosclerosis and provide stronger, earlier signals for atherothrombosis.